Clorox Q4 Profit Plunges 51% as Sales Slip; FY27 Guidance Disappoints
CLX sits 17% above its 52-week low of $84.7.
Summary
Clorox's Q4 earnings missed sharply: net income halved to $163M from $332M a year ago, with EPS dropping to $1.34 from $2.68. Sales slipped 2% to $1.95B. For the full year, EPS fell to $4.81 from $6.52 on a 5% revenue decline. The company guided FY27 adjusted EPS to $5.70-$6.00, below consensus expectations, despite a projected 13-14% sales jump that includes a 9.5-point boost from the GOJO acquisition. Organic growth is seen at just 3.5-4.5%. This follows the CEO's health-related departure in May and a major restructuring announced in June, adding to uncertainty. The after-hours pop of 1.4% may reflect relief that guidance wasn't worse, but the underlying numbers show significant earnings erosion.
At the time of this announcement, CLX was trading at $98.71 on NYSE in the Trade & Services sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $84.70 to $128.90. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.